Cargando…

Hydroxychloroquine and the risk of respiratory infections among RA patients

OBJECTIVES: To determine the effect of hydroxychloroquine on the incidence of new respiratory infections in a large registry of rheumatoid arthritis (RA) patients compared with a matched cohort receiving other conventional disease-modifying antirheumatic drugs (csDMARDs). METHODS: We reviewed physic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kremer, Joel M, Reed, George, Pappas, Dimitrios A, Harold, LR, Kane, Kevin, Greenberg, Jeffrey, Winthrop, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856157/ https://www.ncbi.nlm.nih.gov/pubmed/33161375 http://dx.doi.org/10.1136/rmdopen-2020-001389

Ejemplares similares

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme
por: Yamanaka, Hisashi, et al.
Publicado: (2017)

From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?
por: Molendijk, Marlieke, et al.
Publicado: (2018)

Cluster‐Randomized Trial of a Behavioral Intervention to Incorporate a Treat‐to‐Target Approach to Care of US Patients With Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Time-varying risks of infection in patients as they proceed through the phases of ‘pre-RA’: results from the Scottish Early RA inception cohort
por: Porter, Duncan, et al.
Publicado: (2023)

Genetics of RA susceptibility, what comes next?
por: Ding, James, et al.
Publicado: (2015)

Joint involvement in RA starts predominantly in the hands: functional, clinical and imaging studies in clinically suspect arthralgia and during progression to RA
por: Khidir, Sarah J H, et al.
Publicado: (2023)

Interplay between obesity and smoking with regard to RA risk
por: Hedström, Anna Karin, et al.
Publicado: (2019)

Brief Report: Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Meta-Analysis of Genome-Wide Data
por: McAllister, Kate, et al.
Publicado: (2013)

Interplay between alcohol, smoking and HLA genes in RA aetiology
por: Hedström, Anna Karin, et al.
Publicado: (2019)

JAK inhibition and the holy grail for pain control in early RA
por: Pazmino, Sofia, et al.
Publicado: (2022)

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Hand function is already reduced before RA development and reflects subclinical tenosynovitis
por: Krijbolder, Doortje Isabelle, et al.
Publicado: (2023)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists
por: Hifinger, Monika, et al.
Publicado: (2017)

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry
por: Manders, Sofie H M, et al.
Publicado: (2015)

Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA
por: Platten, Michael, et al.
Publicado: (2017)

Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease
por: Leon, Leticia, et al.
Publicado: (2023)

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set
por: Bykerk, Vivian P, et al.
Publicado: (2016)

Effects of alcohol consumption and smoking on risk for RA: results from a Swedish prospective cohort study
por: Hedenstierna, Louise, et al.
Publicado: (2021)

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
por: Winthrop, Kevin L., et al.
Publicado: (2017)

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
por: Cohen, Stanley B, et al.
Publicado: (2021)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
por: Saleem, Benazir, et al.
Publicado: (2022)

Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
por: Bayat, Sara, et al.
Publicado: (2022)

Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature
por: Karonitsch, Thomas, et al.
Publicado: (2022)

Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database
por: Juge, Pierre-Antoine, et al.
Publicado: (2023)

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
por: Taylor, Peter C, et al.
Publicado: (2022)

Value of imaging detected joint inflammation in explaining fatigue in RA at diagnosis and during the disease course: a large MRI study
por: Matthijssen, X M E, et al.
Publicado: (2021)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
por: Cohen, Stanley B, et al.
Publicado: (2020)

Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial
por: Hebing, Renske CF, et al.
Publicado: (2022)

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
por: Winthrop, Kevin L., et al.
Publicado: (2017)

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Moderate use of alcohol is associated with lower levels of C reactive protein but not with less severe joint inflammation: a cross-sectional study in early RA and healthy volunteers
por: Mangnus, Lukas, et al.
Publicado: (2018)

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
por: Delcoigne, Benedicte, et al.
Publicado: (2022)

Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures
por: Kremer, Joel M, et al.
Publicado: (2016)

Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial
por: Pazmino, Sofia, et al.
Publicado: (2021)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7a6g9mf1pft0ci5m7kau14i54b